Long‐Term Colorectal Cancer Incidence After Adenoma and Serrated Polyp Removal: Results From the Colonprev Trial
United European Gastroenterology Journal · 2026-06 · 14 (5)
DOI: 10.1002/ueg2.70245 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift United European Gastroenterology Journal, online erschienen am 11.06.2026. Verfasst von Joaquín Cubiella und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Hospital Universitario de Ourense, Grupo de Investigación en Oncología Digestiva-Ourense, CIBERehd, Ourense, Spain. Hauptthemen laut MEDLINE: Adenoma, Colonic Polyps, Colorectal Neoplasms. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the Fundación Científica de la Asociación Española contra el Cáncer, Instituto de Salud Carlos III, Agència de Gestió d'Ajuts Universitaris i de Recerca.
Abstract (Originalsprache)
Background
The risk of colorectal cancer (CRC) after serrated polyp resection remains unclear, and current surveillance recommendations rely on limited evidence. We evaluated CRC incidence in individuals with advanced serrated lesions (ASL) detected at baseline colonoscopy and compared risk according to the most advanced lesion identified.
Methods
Participants undergoing colonoscopy within the COLONPREV trial ( n = 8989) were included in this post hoc analysis. Individuals were classified according to the most advanced baseline lesion: no lesion, non‐advanced adenoma, advanced adenoma, or ASL. The primary outcome was incident CRC. Cumulative incidence and hazard ratios (HR) were estimated using Cox proportional hazard models.
Results
At baseline colonoscopy, serrated polyps were detected in 19.8% of participants, including ASL in 2.5%. Over a mean follow‐up of 9.5 years, 44 CRC cases were diagnosed (cumulative incidence 0.49%; incidence rate 0.52 per 1000 person‐years). The 10‐year cumulative incidence was 0.27% in individuals without baseline lesions ( n = 5496), 0.57% in those with non‐advanced adenomas ( n = 2091), 1.23% in advanced adenomas ( n = 1218), and 1.09% in ASL ( n = 184). In multivariable analysis, CRC risk was increased for non‐advanced adenomas (HR 3.25, 95% CI 1.48–7.16), advanced adenomas (HR 9.77, 95% CI 4.24–22.50), and ASL (HR 6.37, 95% CI 1.42–28.54). Surveillance colonoscopy was associated with lower CRC incidence (HR 0.46, 95% CI 0.22–0.95 for one colonoscopy; HR 0.09, 95% CI 0.02–0.40 for ≥ 2 colonoscopies).
Conclusion
In this screening cohort, ASL were associated with increased CRC risk in the range of advanced adenomas. These findings provide risk estimates relevant to post‐polypectomy management. Trial registration number NCT00906997.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Hospital Universitario de Ourense, Grupo de Investigación en Oncología Digestiva-Ourense, CIBERehd, Ourense, Spain.
- Department of Oncology, Hospital Universitario de Ourense, Grupo de Investigación en Oncología Digestiva-Ourense, Ourense, Spain.
- Department of Gastroenterology, Hospital Clínic of Barcelona, IDIBAPS, Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERehd), University of Barcelona, Barcelona, Catalonia, Spain.
- Department of Gastroenterology, Hospital Universitario de Canarias, Instituto Universitario de Tecnologías Biomédicas, Universidad de La Laguna, Tenerife, Spain.
- Department of Hepatology and Gastroenterology, Biogipuzkoa Health Research Institute-Donostia University Hospital, Universidad del País Vasco, CIBERehd, San Sebastián, Spain.
- Colorectal Cancer Screening Program, Dirección General de Salud Pública, Conselleria de Sanitat, Valencia, Spain.
ORCID-Profile: Montserrat Andreu, Cristina Regueiro-Expósito, Pedro Davila-Piñón
Förderung
- the Fundación Científica de la Asociación Española contra el Cáncer
- Instituto de Salud Carlos III
- Agència de Gestió d'Ajuts Universitaris i de Recerca
- Obra Social de Kutxa, Diputación Foral de Gipuzkoa
- Departamento de Sanidad del Gobierno Vasco, EITB-Maratoia
- Conselleria de Sanidade, Xunta de Galicia
- Axencia Galega de Innovación
Zitieren
APA
Cubiella, J., García-Benito, C., Castells, A., Quintero, E., Bujanda, L., Castán-Cameo, S., Díaz-Tasende, J., Lanas, Á., Ono, A., Frías-Arrocha, E., Hernández, C., Jover, R., Andreu, M., Carballo, F., Morillas, J. D., Salas, D., Regueiro-Expósito, C., Davila-Piñón, P., Diez-Martín, A., & COLONPREV study investigators (2026). Long‐Term Colorectal Cancer Incidence After Adenoma and Serrated Polyp Removal: Results From the Colonprev Trial. United European Gastroenterology Journal, 14(5). https://doi.org/10.1002/ueg2.70245
Vancouver
Cubiella J, García-Benito C, Castells A, Quintero E, Bujanda L, Castán-Cameo S, et al. Long‐Term Colorectal Cancer Incidence After Adenoma and Serrated Polyp Removal: Results From the Colonprev Trial. United European Gastroenterology Journal. 2026;14(5). doi:10.1002/ueg2.70245
BibTeX
@article{Cubiella2026,
author = {Cubiella, Joaquín and García-Benito, Carme and Castells, Antoni and Quintero, Enrique and Bujanda, Luis and Castán-Cameo, Susana and Díaz-Tasende, José and Lanas, Ángel and Ono, Akiko and Frías-Arrocha, Eladio and Hernández, Cristina and Jover, Rodrigo and Andreu, Montserrat and Carballo, Fernando and Morillas, Juan Diego and Salas, Dolores and Regueiro-Expósito, Cristina and Davila-Piñón, Pedro and Diez-Martín, Astrid and COLONPREV study investigators, COLONPREV study investigators},
title = {Long‐Term Colorectal Cancer Incidence After Adenoma and Serrated Polyp Removal: Results From the Colonprev Trial},
journal = {United European Gastroenterology Journal},
year = {2026},
volume = {14},
number = {5},
doi = {10.1002/ueg2.70245}
}
EUVIMED